KANSAS CITY, Mo., Aug. 3, 2012 /PRNewswire-USNewswire/ -- MRIGlobal today announced that it has been awarded a 12th consecutive contract from the National Cancer Institute to operate the Anti-Cancer Chemicals and Pharmaceutical Formulations Analysis Program.
The contract, for a five-year term, is valued at $3.8 million. In this continuing program, MRIGlobal performs analysis of bulk pharmaceutical substances and formulated drug products under strict quality control standards known in the industry as "current Good Manufacturing Practices."
"We're proud to be continuing our robust history of support for the National Cancer Institute," said Michael F. Helmstetter, Ph.D., President and Chief Executive Officer of MRIGlobal. "Our work advances the goal of delivering a world without cancer."
MRIGlobal performs analyses that support the development of anti-cancer chemicals and pharmaceuticals that are typically in pre-approval phases, and MRIGlobal's analyses are performed to meet requirements of the U.S. Food and Drug Administration.
MRIGlobal uses spectroscopy, chromatography, and electrochemical analyses, among other complex technical tests, to investigate these drugs. In the 43 years of operation of the program, MRIGlobal has completed more than 2,000 analytical reports on small organic molecules, complex antibiotics, proteins and other compounds.
This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN26201200026C.
For more information, visit www.mriglobal.org .